Bristol Myers Squibb (CELG-RI) Research & Development (2009 - 2026)

Bristol Myers Squibb has disclosed Research & Development across 18 years of filings, most recently posting $2.6 billion for Q1 2026.

• In Q1 2026, Research & Development rose 17.37% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $10.3 billion (down 3.53% YoY), while the FY2025 annual figure was $10.0 billion, down 10.83% from the prior year.
• Research & Development improved to $2.6 billion in Q1 2026, from $2.6 billion in the prior quarter.
• Over the last five years, Research & Development for CELG-RI reached as high as $3.2 billion in Q4 2024 and fell as low as $2.2 billion in Q3 2023.
• The 5-year median for Research & Development is $2.5 billion (2023), against an average of $2.5 billion.
• Annual changes were most pronounced in 2024 — Research & Development advanced 28.77% — and 2025, when it retreated 18.96%.
• A 5-year view of Research & Development shows it stood at $2.5 billion in 2022, then dropped by 1.27% to $2.5 billion in 2023, then increased by 28.77% to $3.2 billion in 2024, then dropped by 18.96% to $2.6 billion in 2025, then rose by 2.44% to $2.6 billion in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.6 billion, $2.6 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.